GYNECOLOGIC CANCERS

An application for approval has been submitted to the FDA for mirvetuximab soravtansine to treat patients with folate receptor alpha-high platinum-resistant ovarian cancer.

The phase 3 CALLA study did not achieve its key end point of progression-free survival improvement with the addition of durvalumab to chemoradiotherapy in patients with locally advanced cervical cancer.

Findings presented during the SGO Annual Meeting show that atezolizumab given prior to concurrent chemoradiation may be safe with immune modulating activity in patients with node-positive, locally advanced cervical cancer.

During a Targeted Oncology case-based roundtable event, Erin Crane, MD, MPH, discussed several phase 3 trials of new combinations for maintenance therapy of advanced ovarian cancer.

In an interview with Targeted Oncology, Annelise Wilhite, MD, discussed the findings of a clinical investigation of survival in patients with vulvar/vaginal melanomas.

Bradley Monk, MD, FACCOG, FACS, discusses the creation and findings of the OUTBACK trial.

Using next-generation sequencing to help inform treatment options is growing in frequency, but the results can be difficult to interpret and implement in clinical practice.

In an interview with Lt Col Yovanni Casablanca, MD, discussed the incorporation of new treatments into the cervical cancer paradigm and provided insight into the necessity of inclusive research with novel therapies.

A phase 2 trial sought to evaluate the efficacy and safety of the combination of anlotinib and sintilimab in patients with recurrent advanced endometrial cancer.

Statistically significant improvement in progression-free survival has been shown with selinexor in patients with advanced or recurrent endometrial cancer, including those with wild-type p53.

Bradley J. Monk, MD, FACOG, FACS, discusses the use of immune checkpoint inhibitors to treat cervical cancer.

According to Bradley J. Monk, MD, FACOG, FACS, cemiplimab achieved better response and a longer overall survival compared with chemotherapy in patients with cervical cancer.

In an interview with Targeted Oncology, David S. Hong, MD, discussed the mark tisotumab vedotin has made on the metastatic cervical cancer landscape thus far.

Ahead of its Prescription Drug User Fee Act target action date, the supplemental biologics license application for cemiplimab as treatment of metastatic cervical cancer has been withdrawn.

Dennis Scribner, Jr, MD, discusses the challenges for reaching patients who are at the greatest risk of developing cervical cancer.

In an interview with Targeted Oncology, Shannon N. Westin, MD, MPH, FACOG, reviewed the recent tweet chat around a high-grade epithelial ovarian cancer case.

Immunotherapy has especially demonstrated broad activity in cervical cancer, fueling development in this area and providing further signs of hope for new treatment options to come into the landscape with greater efficacy and manageable safety profiles.

Margarett C. Ellison, MD, MHA, FACS, FACOG, gynecologic oncologist for Gynecologic Oncology of Tallahassee, a Division of Florida Cancer Specialists & Research Institute, reviews potential immunotherapy treatments for Cervical Cancer Awareness Month.

Phase 3 study findings show that paclitaxel combined carboplatin stands up to the combination of paclitaxel and ifosfamide for the treatment of patients with uterine carcinosarcoma.

In patients with recurrent and/or metastatic cervical cancer, the second-line combination of balstilimab and zalifrelimab may offer meaningful clinical benefit, but further research is needed.

Annelise Wilhite, MD, a gynecology oncology fellow at the University of South Alabama Health, discusses the difficulty in treating vulvar and vaginal melanomas.

David M. O’Malley, MD, discusses the management of adverse events across various regimens for cervical cancer treatment and provides insight on future directions for disease management.

Dr David M. O’Malley comments on emerging agents in the pipeline for the treatment of recurrent/metastatic cervical cancer and shares his approach to the sequencing of therapies.

David M. O’Malley, MD, shares insight on data presented at SITC 2021 on the use of a second-generation, Fc-enhanced anti-CTLA4 antibody, AGEN1181, in patients with advanced cervical cancer as well as other solid tumors.

Dr David M. O’Malley reviews ESMO 2021 updates evaluating the use of combination anti-PD-1 and anti-CTLA4 agents for recurrent and metastatic cervical cancer.